From 1989 to 2000, Mr. Grossman was senior managing director and director of health policy in Hill and Knowlton’s Washington office. He developed and implemented public affairs, communications and crisis management programs for health care, pharmaceutical and food clients. He also counseled clients on policy, strategy, corporate communications, regulation, and legislation.
In 1985, Mr. Grossman was appointed to serve as a Deputy Assistant Secretary for Health in the U.S. Department of Health and Human Services. During his four-year tenure, he was responsible for the development of health policy, planning, and evaluation for the U.S. Public Health Service. Among his accomplishments, he chaired the “long-term care” component of the Secretary’s initiative on catastrophic health care costs, coordinated the President’s response to his Commission on HIV Infection and AIDS, and served as Acting Chair of the Orphan Product Board.
Previously, Mr. Grossman was Health Staff Director and Majority Counsel to the Senate Committee on Labor and Human Resources (now Senate HELP Committee). He was one of the chief Senate negotiators on the Orphan Drug Act of 1983 and on the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman). These laws have had significant and lasting impact on the development of new pharmaceutical products. Earlier in his career, while at the Association of American Medical Colleges, he was an analyst and advocate for the nation’s medical schools.
Mr. Grossman received a J.D. from Georgetown University Law Center in 1976 and a BA from Oberlin College in 1973. In 2006, he co-founded and became the executive director of the FDA Alliance, a coalition to advocate for increased appropriated resources for FDA. In January 2008, the Alliance merged with another advocacy group and became the Alliance for a Stronger FDA. He serves as the organization’s Deputy Executive Director.